ReviewTherapeutic advances in urology2016
Tasquinimod in the treatment of castrate-resistant prostate cancer - current status and future prospects.
Review in Therapeutic advances in urology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 40 citations in OpenAlex.
- Exosomal S100A9 promotes lung metastasis of adenoid cystic carcinoma via activating cancer-associated fibroblasts.Cell death discovery · 2026Article
- S100A8/A9 as a key player in colorectal cancer: from diagnosis to therapeutic targeting.Frontiers in pharmacology · 2026Review
- Spatial pharmacology of anti-cancer immunomodulators: a comprehensive review.Frontiers in pharmacology · 2026Review
- S100A9 enhances tumor immune suppression and cancer cell survival in small cell lung cancer.Cell death & disease · 2025Article
- Targeting the tumor microenvironment, a new therapeutic approach for prostate cancer.Prostate cancer and prostatic diseases · 2025Review
- Aryl hydrocarbon receptor as a drug target in advanced prostate cancer therapy - obstacles and perspectives.Transcription · 2025Review
- S100A9 and HMGB1 orchestrate MDSC-mediated immunosuppression in melanoma through TLR4 signaling.Journal for immunotherapy of cancer · 2024Article
- Role played by MDSC in colitis-associated colorectal cancer and potential therapeutic strategies.Journal of cancer research and clinical oncology · 2024Review
- The Features of Shared Genes among Transcriptomes Probed in Atopic Dermatitis, Psoriasis, and Inflammatory Acne: S100A9 Selection as the Target Gene.Protein and peptide letters · 2024Article
- Novel Multi-Target Agents Based on the Privileged Structure of 4-Hydroxy-2-quinolinone.Molecules (Basel, Switzerland) · 2023Article
- Role of myeloid-derived suppressor cells in tumor recurrence.Cancer metastasis reviews · 2023Review
- Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma.Journal for immunotherapy of cancer · 2023Article
- High expression of S100A2 predicts poor prognosis in patients with endometrial carcinoma.BMC cancer · 2022Article
- Macrophages as a Therapeutic Target in Metastatic Prostate Cancer: A Way to Overcome Immunotherapy Resistance?Cancers · 2022Review
- Evaluation of Class IIa Histone Deacetylases Expression and In Vivo Epigenetic Imaging in a Transgenic Mouse Model of Alzheimer's Disease.International journal of molecular sciences · 2021Article
- Novel Combinatorial Approaches to Tackle the Immunosuppressive Microenvironment of Prostate Cancer.Cancers · 2021Review
- HDAC4 promotes nasopharyngeal carcinoma progression and serves as a therapeutic target.Cell death & disease · 2021Article
- A S100A14-CCL2/CXCL5 signaling axis drives breast cancer metastasis.Theranostics · 2020Article
- DNA vaccines for prostate cancer.Pharmacology & therapeutics · 2017Review
- Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial.The Prostate · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment options have significantly expanded in recent years for men with metastatic castration-resistant prostate cancer (mCRPC), with the routine use of immunotherapy (sipuleucel-T) and novel hormonal agents such as enzalutamide and abiraterone acetate prior to taxane-based chemotherapy or radium-223 radiotherapy. A number of immune checkpoints limit the immune response of the host to metastatic tumor progression in prostate cancer, one of which is an immunosuppressive and pro-angiogenic cell called the myeloid-derived suppressor cell (MDSC). Tasquinimod is a small molecular oral inhibitor of S100A9, a key cell surface regulator of MDSC function, and has shown anti-angiogenic, antitumor and immune-modulatory properties in preclinical models of prostate cancer and other solid tumors. A large randomized phase II trial of tasquinimod in men with chemotherapy-naïve mCRPC demonstrated a significant prolongation in radiographic and symptomatic progression-free survival compared with placebo, which was also associated with improvements in overall survival. Tasquinimod was studied in a global phase III randomized trial in men with bone mCRPC and, while it significantly improved radiographic progression-free survival, this did not result in an overall survival benefit. However, tasquinimod is under evaluation as well as a combination therapy with other systemic agents in prostate cancer and as a single agent in other solid tumors. This review encompasses the preclinical and clinical development of tasquinimod as a therapy for men with prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.